MedPath

Zentiva, k.s.

🇨🇿Czech Republic
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:2
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

210

CIMA_AEMPS:189
EMA:14
PHILIPPINES:6
+1 more agencies

Drug Approvals

Pomalidomide Zentiva

Authorization Status
Authorised
Approval Date
Jul 24, 2024
EMA

Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva

Authorization Status
Authorised
Approval Date
Jul 17, 2017
EMA

Ivabradine Zentiva

Authorization Status
Authorised
Approval Date
Nov 11, 2016
EMA

Ivabradine Zentiva

Authorization Status
Authorised
Approval Date
Nov 11, 2016
EMA

Emtricitabine/Tenofovir disoproxil Zentiva

Authorization Status
Authorised
Approval Date
Nov 9, 2016
EMA

Tenofovir disoproxil Zentiva

Authorization Status
Authorised
Approval Date
Sep 15, 2016
EMA

Duloxetine Zentiva

Authorization Status
Authorised
Approval Date
Aug 20, 2015
EMA

Pregabalin Zentiva

Authorization Status
Authorised
Approval Date
Jul 17, 2015
EMA

Aripiprazole Zentiva

Authorization Status
Authorised
Approval Date
Jun 25, 2015
EMA

Aripiprazole Zentiva

Authorization Status
Authorised
Approval Date
Jun 25, 2015
EMA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

A Study Designed to Evaluate the Pharmacokinetic Profile of Abiraterone

Phase 1
Completed
Conditions
Pharmacokinetics
Interventions
First Posted Date
2020-03-04
Last Posted Date
2020-03-04
Lead Sponsor
Zentiva, k.s.
Target Recruit Count
33
Registration Number
NCT04295161
Locations
🇬🇧

Quotient Sciences, Ruddington, United Kingdom

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.